The NM_000152.5:c.1003G>A variant in GAA is a missense variant predicted to cause substitution of glycine by arginine at amino acid 335 (p.Gly335Arg). At least 4 patient(s) with this variant had documented GAA deficiency with <10% of normal mean control level of GAA activity in leukocytes, lymphocytes, muscle samples or were reported to be on enzyme replacement therapy for Pompe disease (PP4_Moderate) (PMIDs 31510962, 26497565, 31193175, 24685124). One of these probands is compound heterozygous for the variant and a variant classified as pathogenic by the ClinGen LSD VCEP, c.876C>G p.Tyr292X (PMID 31510962); the variants were confirmed in trans by familial testing (PM3). The highest population minor allele frequency in gnomAD v4.1.0 for this variant is 0.000011 (1/91090) alleles) in the South Asian population, which is lower than the ClinGen Lysosomal Diseases VCEP’s threshold for PM2_Supporting (<0.001), meeting this criterion (PM2_Supporting). Expression of the variant in COS7 or HEK293 cells resulted in 0.8% GAA activity in cells and evidence of abnormal synthesis and processing on Western blot, indicating that this variant may impact protein function (PMID 22644586)(PS3_Moderate). The computational predictor REVEL gives a score of 0.919 which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3). Another missense variant, c.1004G>A (p.Gly335Glu), in the same codon has been reported in a patient with Pompe disease (PMIDs 22644586, 32711049). This variant has been classified as likely pathogenic by the ClinGen Lysosomal Diseases VCEP. Since c.1003G>A (p.Gly335Arg) was used to apply PM5 in the classification of c.1004G>A (p.Gly335Glu), PM5 is not included here to avoid circular logic (PM5 not met). There is a ClinVar entry for this variant (Variation ID: 972790; 3 star review status) with six submitters classifying the variant as pathogenic. In summary, this variant meets the criteria to be classified as Likely Pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria met, based on the specifications of the ClinGen Lysosomal Diseases VCEP (Specifications Version 2.0.0): PM3, PS3_Moderate, PP4_Moderate, PP3, PM2_Supporting. (Classification approved by the Lysosomal Diseases VCEP, June 17, 2025).